Cargando…
Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation
BACKGROUND: HIFU has been shown to be a more suitable alternative for the treatment of primary solid tumors and metastatic diseases than other focal heat ablation techniques due to its noninvasive and extracorporeal nature. However, similar to other focal heat ablation techniques, HIFU is still in n...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339192/ https://www.ncbi.nlm.nih.gov/pubmed/25710485 http://dx.doi.org/10.1371/journal.pone.0117358 |
_version_ | 1782358853322539008 |
---|---|
author | Li, Juan Krupka, Tianyi Yao, Jinpeng Wang, Ronghui Jiang, Lin Zhou, Yang Zuo, Guoqing Wang, Zhibiao Dai, Lili Ren, Jianli Zheng, Yuanyi Wang, Dong |
author_facet | Li, Juan Krupka, Tianyi Yao, Jinpeng Wang, Ronghui Jiang, Lin Zhou, Yang Zuo, Guoqing Wang, Zhibiao Dai, Lili Ren, Jianli Zheng, Yuanyi Wang, Dong |
author_sort | Li, Juan |
collection | PubMed |
description | BACKGROUND: HIFU has been shown to be a more suitable alternative for the treatment of primary solid tumors and metastatic diseases than other focal heat ablation techniques due to its noninvasive and extracorporeal nature. However, similar to other focal heat ablation techniques, HIFU is still in need of refinements due to tumor recurrence. METHODS: In this work, we investigated the effectiveness of an adjunct treatment regimen using doxorubicin (DOX)-loaded, injectable, in situ-forming, and phase-inverting PLGA as the second line of defense after HIFU ablation to destroy detrimental residual tumors and to prevent tumor recurrence. All of the statistical analyses were performed using the Statistical Package for the Social Sciences 18.0(SPSS, Inc., Chicago, IL, USA), and p< 0.05 was considered statistically significant. All of the results are presented as the means ± STDEV (standard deviation). For multiple comparisons, ANOVA (differences in tumor volumes, growth rates, apoptosis, proliferation indexes, and Bcl-2 and Bax protein levels) was used when the data were normally distributed with homogenous variance, and rank sum tests were used otherwise. Once significant differences were detected, Student-t tests were used for comparisons between two groups. RESULTS: Our results revealed that DOX diffused beyond the ablated tissue regions and entered tumor cells that were not affected by the HIFU ablation. Our results also show that HIFU in concert with DOX-loaded PLGA led to a significantly higher rate of tumor cell apoptosis and a lower rate of tumor cell proliferation in the areas beyond the HIFU-ablated tissues and consequently caused significant tumor volume shrinkage (tumor volumes:0.26±0.1,1.09±0.76, and 1.42±0.9cm(3) for treatment, sham, and no treatment control, respectively). CONCLUSIONS: From these results, we concluded that the intralesional injection of DOX-loaded PLGA after HIFU ablation is significantly more effective than HIFU alone for the treatment of solid tumors. |
format | Online Article Text |
id | pubmed-4339192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43391922015-03-04 Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation Li, Juan Krupka, Tianyi Yao, Jinpeng Wang, Ronghui Jiang, Lin Zhou, Yang Zuo, Guoqing Wang, Zhibiao Dai, Lili Ren, Jianli Zheng, Yuanyi Wang, Dong PLoS One Research Article BACKGROUND: HIFU has been shown to be a more suitable alternative for the treatment of primary solid tumors and metastatic diseases than other focal heat ablation techniques due to its noninvasive and extracorporeal nature. However, similar to other focal heat ablation techniques, HIFU is still in need of refinements due to tumor recurrence. METHODS: In this work, we investigated the effectiveness of an adjunct treatment regimen using doxorubicin (DOX)-loaded, injectable, in situ-forming, and phase-inverting PLGA as the second line of defense after HIFU ablation to destroy detrimental residual tumors and to prevent tumor recurrence. All of the statistical analyses were performed using the Statistical Package for the Social Sciences 18.0(SPSS, Inc., Chicago, IL, USA), and p< 0.05 was considered statistically significant. All of the results are presented as the means ± STDEV (standard deviation). For multiple comparisons, ANOVA (differences in tumor volumes, growth rates, apoptosis, proliferation indexes, and Bcl-2 and Bax protein levels) was used when the data were normally distributed with homogenous variance, and rank sum tests were used otherwise. Once significant differences were detected, Student-t tests were used for comparisons between two groups. RESULTS: Our results revealed that DOX diffused beyond the ablated tissue regions and entered tumor cells that were not affected by the HIFU ablation. Our results also show that HIFU in concert with DOX-loaded PLGA led to a significantly higher rate of tumor cell apoptosis and a lower rate of tumor cell proliferation in the areas beyond the HIFU-ablated tissues and consequently caused significant tumor volume shrinkage (tumor volumes:0.26±0.1,1.09±0.76, and 1.42±0.9cm(3) for treatment, sham, and no treatment control, respectively). CONCLUSIONS: From these results, we concluded that the intralesional injection of DOX-loaded PLGA after HIFU ablation is significantly more effective than HIFU alone for the treatment of solid tumors. Public Library of Science 2015-02-24 /pmc/articles/PMC4339192/ /pubmed/25710485 http://dx.doi.org/10.1371/journal.pone.0117358 Text en © 2015 Li et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Li, Juan Krupka, Tianyi Yao, Jinpeng Wang, Ronghui Jiang, Lin Zhou, Yang Zuo, Guoqing Wang, Zhibiao Dai, Lili Ren, Jianli Zheng, Yuanyi Wang, Dong Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation |
title | Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation |
title_full | Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation |
title_fullStr | Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation |
title_full_unstemmed | Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation |
title_short | Liquid-Solid Phase-Inversion PLGA Implant for the Treatment of Residual Tumor Tissue after HIFU Ablation |
title_sort | liquid-solid phase-inversion plga implant for the treatment of residual tumor tissue after hifu ablation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339192/ https://www.ncbi.nlm.nih.gov/pubmed/25710485 http://dx.doi.org/10.1371/journal.pone.0117358 |
work_keys_str_mv | AT lijuan liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT krupkatianyi liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT yaojinpeng liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT wangronghui liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT jianglin liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT zhouyang liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT zuoguoqing liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT wangzhibiao liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT dailili liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT renjianli liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT zhengyuanyi liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation AT wangdong liquidsolidphaseinversionplgaimplantforthetreatmentofresidualtumortissueafterhifuablation |